Privately-held Californian firm Parvus Therapeutics has entered into an exclusive worldwide license collaboration and option agreement with US pharma major AbbVie (NYSE: ABBV).
The collaboration is for the development and commercialization of novel treatments for inflammatory bowel disease (IBD), using Parvus’ Navacim Treg immune tolerization platform technology.
Navacims present multivalent peptide major histocompatibility complexes to T cells, triggering the endogenous expansion and differentiation of the T cells into antigen-specific Tregs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze